MedTrace Logo

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

NCT02250313 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2018-07-26

No results posted yet for this study

Summary

The main hypothesis of this study is to demonstrate that the use of the ConfirmMDx for Prostate Cancer test in previously biopsied patients improves urologists' patient management by reducing unnecessary repeat biopsies, attendant procedure costs, and potential adverse events in men being considered for a repeat procedure.

Conditions

Sponsors & Collaborators

  • MDx Health

    lead INDUSTRY

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250313 on ClinicalTrials.gov